Key facts
as of Sep 2026- Polaris Genomics’s last known valuation is $9.0M (Nov 2020).
- It has raised $6.2M across 1 recorded rounds; the latest was Seed Round ($1.8M) in Nov 2020.
- Notable investors include Viking Global Investors, Endless Frontier Labs, TEDCO, Wing Venture Capital, Future Labs — 13 tracked in total.
- 1 institutional filer reports fund marks on Polaris Genomics across 2 filings.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Polaris Genomics
Recorded secondary trades
No secondary trades in Polaris Genomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
1 filers · latest Feb 20261 SEC-registered fund reported 2 fair-value marks on Polaris Genomics between Nov 2025 and Feb 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
1 roundsAbout Polaris Genomics
Developer of an evidence-based diagnostics and therapeutics platform designed to reduce suicide, stigma, and suffering in silence. The company platform brings biological clarity and objectivity to the assessment, diagnosis, and treatment of neuropsychiatric conditions, decodes the biological fingerprints of mental health, and advances a range of discovery tools and diagnostics for mental health conditions for populations, enabling clinicians to confidently and quickly assess a person's risk of experiencing stress dysregulation associated with post-traumatic stress disorder (PTSD).
- Industry
- Other Pharmaceuticals and Biotechnology
- Sector
- Healthcare
- HQ
- Gaithersburg, MD, United States
- Founded
- 2017
- Employees
- 10
- Website
- polarisgenomics.com/
- Ownership
- Privately Held (backing)